8:00 am Check-In & Networking
8:50 am Chair’s Opening Remarks
Showcasing Brand New Approaches to Conjugate Design to Overcome the Limitations of Traditional ADCs & Widen the Therapeutic Index
9:00 am Hormone-Peptide Conjugate: Next Generation Targeted Therapy
Synopsis
- Explore a paradigm shift in conjugate design, focusing on the mechanism rather than the molecule, to unlock new avenues for targeted therapy innovations
- Embrace innovation, this conjugate design bypasses traditional linker-based approaches, with the hormone directly fused to the lytic peptide, optimizing delivery and enhancing therapeutic efficacy
- Discover how the unique design of hormone-linked lytic peptides, leveraging electrostatic interactions for targeted cytotoxicity, offers a safer and more effective approach to cancer therapy
9:30 am Spotlighting Synergy: Embracing a Holistic & High-Throughput Approach to Revolutionise the Development of Fragment-Based Novel Conjugate Drugs
Synopsis
- Explore the paradigm shift towards a holistic approach to conjugate design, where equal emphasis is placed on optimizing each component – from payload to linker to targeting binders – to maximize therapeutic efficacy and minimize off-target effects
- Delve into the innovative methodologies enabling rapid iteration and high-throughput screening of conjugates, allowing for the creation of thousands of optimized candidates in mere weeks, revolutionising the pace and scale of conjugate development
- Discuss the transformative potential of integrated whole molecule approaches in driving forward the field of conjugate therapies, ushering in a new era of precision medicine by leveraging comprehensive optimization across all facets of conjugate design and development
10:00 am Speed Networking
Synopsis
Join us for an exhilarating session of speed networking to kick-start the conference. Connect with industry peers, exchange insights, and forge valuable partnerships in just minutes, accelerating your professional network in the dynamic and fast-growing world of novel drug conjugates.
11:00 am Antibody-Like Domains: Pioneering Novel Conjugates for Inflammation Therapy
Synopsis
- Explore the unique properties of soloMERs and their potential as versatile targeting moieties for novel conjugate designs in inflammation therapy
- Discuss the evolution of soloMERs from traditional ADCs in oncology to novel applications in inflammation therapy, highlighting the adaptability and versatility of the platform in addressing diverse disease indications
- Delve into the frontier of novel anti-inflammatory payloads, showcasing the potential for targeted delivery of novel therapeutics in inflammation-related disorders
11:30 am A Transformational Drug Delivery Technology: Using Stabilised PepPeptides to Deliver Proteins and RNA-Targeting Payloads to the Cell Interior
Synopsis
- Improving cellular penetration and stability of biomolecular medicines.
- Enabling the delivery of diverse payloads in specific tissues in the body, allowing for a disease-agnostic approach.
- Varying the number and placement of staples on peptides to determine the most effective conformation in combination with different payloads
12:00 pm Lunch & Networking
Highlighting Application of Oligonucleotide Conjugates for Precise Modulation of Gene Expression in Diverse Therapeutic Areas
1:00 pm Overcoming Endosomal Entrapment in Oligonucleotide Delivery
Synopsis
- Explore the challenges of endosomal entrapment in delivering oligonucleotide payloads and the critical role of endosomal escape enhancers in maximising intracellular delivery and therapeutic efficacy
- Discuss the evolution of antibody-oligonucleotide conjugates as promising modalities for RNA therapies, and the imperative of enhancing endosomal escape for effective delivery beyond hepatic targets
- Showcasing a diverse portfolio of proof-of-concept studies demonstrating the efficacy of endosomal escape enhancers in facilitating intracellular release of oligonucleotide payloads, paving the way for transformative therapeutics with the potential to revolutionize patient care
1:30 pm GEENIE: A Novel Protein Nanoneedle for Targeted Intracellular Delivery
Synopsis
- Mechanism of cell entry: Bypasses endosomes to deliver a diverse range of therapeutic cargoes directly into cells Therapeutic Applications: Enhances the efficacy of drugs, nucleotides, and other therapeutic agents by avoiding degradation
- Innovative Design: Designing protein nanoneedles for targeted delivery without using antibodies
2:00 pm Gene Silencing Redefined: Unlocking the Potential of Self-Delivering siRNAs
Synopsis
- Which delivery technologies are gaining acceptance?
- Advantages of lipid siRNAs
- PRAMOMOLECULAR´s self-delivering siRNAs
2:30 pm Afternoon Break & Networking
Harnessing Bispecific Drug Conjugates For Enhanced Target Specificity & a Reduction in Off-Target Toxicity
3:00 pm New PEGylated Bispecific ADC
Synopsis
- Achieving excellent tumour penetration
- Optimising internalization and lysosome trafficking, no efflux
- Benefiting from no Fc induced toxicity
- Highly selective toward tumor cells
3:30 pm Pushing the Envelope: Developing Bi-Specific ADCs Using a Novel GlycOBI™ Platform
Synopsis
- Advantages of Dual Targeting: Enhancing efficacy by targeting multiple tumour proteins simultaneously, combats resistance with varied mechanisms of action, and broadens the target patient populations
- Challenges and Target Selection: Selecting the optimal targets and ideal formats remains complex, requiring precise identification of tumor-specific proteins for effective dual targeting
- Benefits of GlycOBI™ Platform: Producing homogenous ADCs without genetic modification, enhancing stability and anti-tumor activity with hydrophilic linkers, and simplifying the Chemistry, Manufacturing, and Controls (CMC) process
4:00 pm Targeted Delivery of Synthetic Cargos via Bispecific Antibodies: An Affinity-Based Conjugation Platform
Synopsis
- Utilising bispecific antibodies to precisely bind and deliver synthetic cargos to specific cellular targets
- Enhancing the specificity and efficiency of synthetic cargo delivery to designated cells
- Offering a versatile platform for targeted therapeutic applications by leveraging affinity based interactions for precise cargo delivery